20240041900. GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS simplified abstract (The Johns Hopkins University)
GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS
Organization Name
Inventor(s)
Barbara Slusher of Kingsville MD (US)
David Volsky of Scarsdale NY (US)
Mike Nedelcovych of Richmond VA (US)
Kristen Hollinger of Parkton MD (US)
Atsushi Kamiya of Pikesville MD (US)
GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240041900 titled 'GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS
Simplified Explanation
The abstract of the patent application describes a group of compounds and their pharmaceutically acceptable salts for use in treating cognitive deficits and psychiatric disorders associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and HIV-associated neurocognitive disorders (HAND). These compounds are prodrugs that release glutamine analogs, specifically 6-diazo-5-oxo-l-norleucine (DON).
- The compounds described in the patent application are prodrugs that release glutamine analogs.
- These compounds and their pharmaceutically acceptable salts can be used to treat cognitive deficits and psychiatric disorders associated with various conditions.
- The specific conditions mentioned include neurological or neurodegenerative disorders, psychiatric or mood disorders, and HIV-associated neurocognitive disorders (HAND).
Potential applications of this technology:
- Treatment of cognitive deficits associated with neurological or neurodegenerative disorders such as Alzheimer's disease or Parkinson's disease.
- Treatment of psychiatric disorders such as depression, anxiety, or schizophrenia.
- Treatment of HIV-associated neurocognitive disorders (HAND).
Problems solved by this technology:
- Cognitive deficits and psychiatric disorders associated with various conditions can be effectively treated.
- The release of glutamine analogs through prodrugs provides a targeted approach for addressing these disorders.
Benefits of this technology:
- Improved cognitive function and mental well-being for individuals suffering from cognitive deficits and psychiatric disorders.
- Potential for more targeted and effective treatment compared to existing therapies.
- Possibility of addressing multiple conditions with a single compound or class of compounds.
Original Abstract Submitted
and the pharmaceutically acceptable salts thereof, wherein r, r, r′, and x are as defined as set forth in the specification, for use in treating cognitive deficits and/or psychiatric disorders, such as those associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and hiv-associated neurocognitive disorders (hand). compounds having formula (i) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-l-norleucine (don).
